Our pipeline consists of two apical sodium-dependent bile acid transporter (ASBT) inhibitors which are being studied across six cholestatic liver diseases in children and adults.
Maralixibat is an orally administered medication in clinical development for children with Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia.
In addition, we are evaluating volixibat, also an oral drug, in clinical studies for the treatment of cholestatic diseases including primary sclerosing cholangitis (PSC), intrahepatic cholestasis of pregnancy (ICP), and primary biliary cholangitis (PBC).
Each of these conditions, if left untreated, can lead to serious complications including a significant impact to the quality of life for both patients and their families.
Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning many years and patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their lives back.